Christina X Chamberlain
Overview
Explore the profile of Christina X Chamberlain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
569
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chamberlain C, Morga A, Song Y, Edwards M, Anderson A, Sarathy K, et al.
Clin Ophthalmol
. 2025 Feb;
19:599-615.
PMID: 39990746
Purpose: To investigate impacts of dry age-related macular degeneration (AMD) on patients and caregivers. Patients And Methods: Semi-structured interviews were conducted with patients with dry AMD, caregivers, and controls (individuals...
2.
Morga A, Chamberlain C, Meyers O, Roberts C, Gaspar L, Su J
Ophthalmol Ther
. 2023 Feb;
12(2):1181-1193.
PMID: 36781630
Introduction: Geographic atrophy (GA) occurs in the later stages of dry age-related macular degeneration (AMD) and impairs visual acuity, eventually causing permanent blindness in some patients and impacting patient quality...
3.
Zhu A, Macarulla T, Javle M, Kelley R, Lubner S, Adeva J, et al.
JAMA Oncol
. 2021 Sep;
7(11):1669-1677.
PMID: 34554208
Importance: Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20% of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free survival as determined by central review was significantly...
4.
Chamberlain C, Faust E, Goldschmidt D, Webster N, Boscoe A, Macaulay D, et al.
J Gastrointest Oncol
. 2021 May;
12(2):658-668.
PMID: 34012657
Background: Advanced cholangiocarcinoma (CCA) is associated with considerable morbidity and mortality. Novel second-line treatments for advanced CCA underscore the need to understand treatment patterns and economic burden of illness in...
5.
Abou-Alfa G, Macarulla T, Javle M, Kelley R, Lubner S, Adeva J, et al.
Lancet Oncol
. 2020 May;
21(6):796-807.
PMID: 32416072
Background: Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a poor clinical outcome. The aim of this international phase...